Presentation is loading. Please wait.

Presentation is loading. Please wait.

Main Figures and Tables. Figure 1 Strategy (shall we make a strategy figure here?? ）

Published byDeborah Thompson Modified over 9 years ago

Similar presentations

Presentation on theme: "Main Figures and Tables. Figure 1 Strategy (shall we make a strategy figure here?? ）"— Presentation transcript:

1 Main Figures and Tables

2 Figure 1 Strategy (shall we make a strategy figure here?? ）

3 Figure 2. ab Need to replaced by the final figures highlow samples proteins cancercontrol ZW: we can cut the samples labels

4 Figure 3. Signaling pathway analysis of the differential proteins (pathway will be generated either by IPA or KEGG)

5 Table 1.

6 Figure 4.

7 MELK in Adenocacinoma Figure 5. DAPK2 MELK MELK in Squamouse cell carcinoma

8 Table 2. Correlation analysis

9 Supplementary Figures

10 Supplementary Figure S1 – PCA Analysis proteins ABC control cancer control cancer PCA on samples without any filter PCA on samples with p<0.05 PCA on proteins with p<0.05

11 EGFR Squamouse cell carcinoma Adenocarcinoma P = 0,006231 P = 0,03599 high expression Overall Survival Probability low expression high expression low expression Overall Survival [months] Overall Survival Probability 050100 150 200 Overall Survival [months] 0.0 0.2 0.4 0.6 0.8 1.0 050100 150 200 Overall Survival [months] 0.0 0.2 0.4 0.6 0.8 1.0 Supplementary Figure S2

12 DAPK2 Adenocarcinoma & Squamouse cell carcinoma P = 0,008825 low expression (n=45) high expression (n=275) Overall Survival Probability 050 100 150 200 Overall Survival [months] 0.0 0.2 0.4 0.6 0.8 1.0 Supplementary Figure S3 a.

13 DAPK2 P = 0,0198 P = 0,03282 low expression (n=33) high expression (n=113) Overall Survival Probability low expression (n=12) high expression (n=162) 050100 150 200 Overall Survival [months] 0.0 0.2 0.4 0.6 0.8 1.0 050100 150 200 Overall Survival [months] 0.0 0.2 0.4 0.6 0.8 1.0 Squamouse cell carcinoma Adenocarcinoma b.c.

14 MELK Adenocarcinoma & Squamouse cell carcinoma P = 0,043 low expression (n=68) high expression (n=291) Overall Survival Probability 050100 150 200 Overall Survival [months] 0.0 0.2 0.4 0.6 0.8 1.0 Supplementary Figure S4 a.

15 MELK low expression (n=40) high expression (n=139) P = 0,017 Overall Survival Probability P = 0,69 low expression (n=28) high expression (n=153) Overall Survival [months] 0.0 0.2 0.4 0.6 0.8 1.0 050100 150 200 Overall Survival [months] 0.0 0.2 0.4 0.6 0.8 1.0 050100 150 200 Overall Survival [months] 0.0 0.2 0.4 0.6 0.8 1.0 Squamouse cell carcinoma Adenocarcinoma b.c.

16 DDR1 P = 0,0485 moderate expression (n=100) high expression (n=54) Overall Survival Probability Overall Survival [months] P = 0,7228 low expression (n=29) high expression (n=20) low expression (n=157) Overall Survival [months] 050100 150 200 Overall Survival [months] 0.0 0.2 0.4 0.6 0.8 1.0 050100 150 200 Overall Survival [months] 0.0 0.2 0.4 0.6 0.8 1.0 Squamouse cell carcinoma Adenocarcinoma b.c.

Download ppt "Main Figures and Tables. Figure 1 Strategy (shall we make a strategy figure here?? ）"

Similar presentations

1+b-c Figure S1 | Number of patches that contain a single helper (s). 1+b 1-c 1+b-c 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1+b 1-c 1+b-c.

1+b-c Figure S1 | Number of patches that contain a single helper (s). 1+b 1-c 1+b-c b 1-c 1+b-c.
P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.
Gene Set Enrichment Analysis (GSEA)

Gene Set Enrichment Analysis (GSEA)
100 200 300 400 500 Dilation Rotation Trans- Lation/refle ction Angle of polygons More Angle pairs Angle Word problems Angle pairs 500 100 200 300 400.

Dilation Rotation Trans- Lation/refle ction Angle of polygons More Angle pairs Angle Word problems Angle pairs
Supplemental Figures. Supplemental Figure 1. Top two canonical pathways clustering the potential predictive biomarkers. The Ingenuity IPA tool was used.

Supplemental Figures. Supplemental Figure 1. Top two canonical pathways clustering the potential predictive biomarkers. The Ingenuity IPA tool was used.
Supplemental figure 1: Correlation coefficients between signal intensities from biological replicates of wild.

Supplemental figure 1: Correlation coefficients between signal intensities from biological replicates of wild.
Huidi Liu, M.D. & Ph.D Genomics Research Centre Harbin Medical University, China Reduced expression of SOX7 in ovarian cancer: a novel.

Huidi Liu, M.D. & Ph.D Genomics Research Centre Harbin Medical University, China Reduced expression of SOX7 in ovarian cancer: a novel.
Gene Expression Signatures for Prognosis in NSCLC, Coupled with Signatures of Oncogenic Pathway Deregulation, Provide a Novel Approach for Selection of.

Gene Expression Signatures for Prognosis in NSCLC, Coupled with Signatures of Oncogenic Pathway Deregulation, Provide a Novel Approach for Selection of.
Supplementary table 1 miR-506 expression and clinocopathological factors FactorsTotal number miR-506 low expressionmiR-506 high expression P-value (n =

Supplementary table 1 miR-506 expression and clinocopathological factors FactorsTotal number miR-506 low expressionmiR-506 high expression P-value (n =
Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets.

Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets.
Idea: measure the amount of mRNA to see which genes are being expressed in (used by) the cell. Measuring protein might be more direct, but is currently.

Idea: measure the amount of mRNA to see which genes are being expressed in (used by) the cell. Measuring protein might be more direct, but is currently.
(3408983) 2.2 FC autism control FGR1OP2. (3806939) 1.4 FC autism control SMAD2.

( ) 2.2 FC autism control FGR1OP2. ( ) 1.4 FC autism control SMAD2.
Supplementary Figure B-1. Bile acid biosynthesis pathway in Metformin therapy group.

Supplementary Figure B-1. Bile acid biosynthesis pathway in Metformin therapy group.
Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer.

Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer.
Circuits & Boolean Expressions. A ABC BC ABC C B A Example # 1: Boolean Expression: Develop a Boolean expression from a circuit.

Circuits & Boolean Expressions. A ABC BC ABC C B A Example # 1: Boolean Expression: Develop a Boolean expression from a circuit.
Supplemental Figure 1 Expression of UHRF1 detected by TaqMan qRT-PCR and many characteristics of patients were compared by Mann-Whiteney’s U-test. A. Expression.

Supplemental Figure 1 Expression of UHRF1 detected by TaqMan qRT-PCR and many characteristics of patients were compared by Mann-Whiteney’s U-test. A. Expression.
Supplementary Figure 1: Correlation analysis of DKC1 mRNA and dyskerin protein quantity in neuroblastoma cell lines.

Supplementary Figure 1: Correlation analysis of DKC1 mRNA and dyskerin protein quantity in neuroblastoma cell lines.
Supplementary Figure 1 Supplementary Figure 1. Representative micrographs of migration and invasion assays. miR-452 or si-WWP1 transfectants inhibited.

Supplementary Figure 1 Supplementary Figure 1. Representative micrographs of migration and invasion assays. miR-452 or si-WWP1 transfectants inhibited.
AB Financial Support: CNPq, Fundação do Câncer, - Fiocruz 30/2006, Proteomic core facility from Fiocruz – PR, PDTIS. Epigenetic and proteomic analysis.

AB Financial Support: CNPq, Fundação do Câncer, - Fiocruz 30/2006, Proteomic core facility from Fiocruz – PR, PDTIS. Epigenetic and proteomic analysis.
Digital Logic Design. Truth Table  Logic Circuit 1. Start with truth table 2. When your output is a 1, figure out the combination of inputs, ANDs, and.

Digital Logic Design. Truth Table  Logic Circuit 1. Start with truth table 2. When your output is a 1, figure out the combination of inputs, ANDs, and.

Similar presentations

Ads by Google